Healthgen Biotech won the "Gold Award of the 2nd High-value Patent Competition of Hubei Province " April 20, 2022, the "2022 National Intellectual Property Publicity Week Launching Ceremony" and award ceremony of "The 2nd High-value Patent Competition of Hubei Province" hosted by the Hubei Provincial Intellectual Property Office were held at the Hubei Science and Technology Mu... Posted by Site editor|2022-04-20 LearnMore
Phase II clinical study of plant-derived recombinant human serum albumin achieved phased results The HY1001 project (plant-derived Recombinant human serum albumin injection) of Wuhan Healthgen Biotechnology Corp. (hereinafter referred to as  “Healthgen Biotech”), Phase II clinical study completed the enrollment of all subjects in the first cohort. On January 12, 2022, after ... Posted by Site editor|2022-01-14 LearnMore
The world's first recombinant protein drug for the treatment of emphysema has been approved by the US FDA for clinical research January 13, 2022, Wuhan Healthgen Biotechnology Corp. (hereinafter referred to as  “Healthgen Biotech”) received the approval of the US Food and Drug Administration (For short "FDA") for the clinical trial of Alpha 1-antitrypsin (AAT) for injection (Project No. HY1003) independen... Posted by Site editor|2022-01-13 LearnMore
Recombinant Human Serum Albumin used in cell therapy serum-free cell culture Since the development of low serum/serum-free culture technology, human serum albumin has been widely used in the research and application of replacing serum. The main functions of human serum albumin in cell culture are as follows:    1. Maintain the osmotic pre... Posted by Site editor|2022-01-14 LearnMore
Application of OsrHSA in in vitro diagnostic (IVD) In Vitro Diagnosis (IVD) refers to extract blood, body fluids, tissues and other samples from the human body, and use in vitro testing reagents and instruments to test and calibrate the samples, which are divided into three major categories according to the methodology: biochemic... Posted by Site editor|2021-11-16 LearnMore
Pre 1 2 3 4 5 6 Next

Wuhan Healthgen Biotechnology Corp.

Tel. +86 027 59301891 Ext 8015

Fax. +86 027 59403931

E-mail cjing@oryzogen.com

268 Shendun 5th Road, East Lake High-Tech Development Zone, Wuhan, China 430020

Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3